Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits

Clinica Chimica Acta

Volumn 336, Issue 1-2, 2003, Pages 103-108

  Zhao, Shui Ping ^a   Zhang, Da Qing ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Adipocytes; Atorvastatin; Hypercholesterolemia; Interleukin 6; PPAR

Indexed keywords

ATORVASTATIN; CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ADIPOCYTE MEMBRANE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ORYCTOLAGUS CUNICULUS;

EID: 0142247143     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00335-8     Document Type: Article

References (31)

1. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
2. Weinhold B., Bader A., Polis V., Ruther U. Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem. J. 325:1997;617.
3. Yeh E.T.H., Willerson J.T. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 107(3):2003;370-371.
4. Koenig W., Sund M., Frohlich M.et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242.
5. Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 22:1998;1145-1158.
6. Greenberg A.S., Nordan R.P., Mcintosh J.et al. Interleukin-6 lowers adipocyte lipoprotein lipase activity in vivo and in vitro. Clin. Res. 38:1991;455A.
7. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 8:1999;253-278.
8. Lindmark E., Diderholm E., Wallentin L.et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 286(17):2001;2107- 2113.
9. Ridker P.M., Rifai N., Stampfer M.J.et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101(15):2000;1767-1772.
10. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60(3):2001;329-339.
11. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocoticoid. J. Clin. Endocrinol. Metab. 83(3):1998;847-850.
12. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105(9):2002;1135-1143.
13. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21(11):2001;1712-1719.
14. Bustos C., Hernandez-Presa A., Ortego M.et al. HMG-coA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32(7):1998;2057-2064.
15. Rodbell M. Effects of hormones on glucose metabolism and lipolysis. J. Biol. Chem. 239:1963;375-380.
16. Zhang H.H., Kumar S., Barnett A.H., Eggo M.C. Ceiling culture of mature human adipocytes: use in studies of adipocyte functions. J. Endocrinol. 164(2):2000;119-128.
17. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 28:1979;5294-5299.
18. Musiap J., Undas A., Gajewski P.et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int. J. Cardiol. 77(2-3):2001;247-253.
19. Han S.N., Leka L.S., Lichtenstein A.H., Ausman L.M.et al. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J. Lipid Res. 43(3):2002;445-452.
20. Ikeda U., Shimada K. The anti-inflammatory effects of statins. N. Engl. J. Med. 345(16):2001;1210.
21. Plenge J.K., Hernandez T.L., Weil K.M.et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 106(12):2002;1447-1452.
22. Massy Z.A., Kim Y., Guijarro C., Kasiske B.L., Keane W.F., O'Donnell M.P. Low-density lipoprotein-induced expression of interleukin-6, a marker of human messangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem. Biophys. Res. Commun. 267(2):2000;536-540.
23. Niemann-Jonsson A., Dimayuga P., Jovinge S.et al. Accumulation of lDL in rat Arteries is associated with activation of tumor necrosis factor-a expression. Arterioscler. Thromb. Vasc. Biol. 20:2000;2205-2211.
24. Rezaie-Majd A., Maca T., Bucek R.A.et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22:2002;1194-1199.
25. Ito T., Ikeda U., Shimpo M., Ohki R., Takahashi M., Yamamoto K.et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc. Drugs Ther. 16(2):2002;121-126.
26. Grip O., Janciauskiene S., Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm. Res. 51(2):2002;58-62.
27. Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res. 45(2):2002;147-154.
28. Barbier O., Torra I.P., Duguay Y.et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22:2002;717-726.
29. Kliewer S.A., Lehmann J.M., Willson T.M. Orphan nuclear receptors: shifting endocrinology into reverse. Science. 284:1999;757-760.
30. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M.et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol. 164(12):2000;6503-6508.
31. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 101(3):2000;235-238.